Pyxis Oncology Q1 EPS Estimate Increased by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – HC Wainwright increased their Q1 2025 EPS estimates for Pyxis Oncology in a research note issued on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.29) for the quarter, up from their prior estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Trading Up 8.0 %

Shares of NASDAQ:PYXS opened at $1.21 on Friday. The company has a 50-day moving average price of $1.33 and a 200 day moving average price of $2.35. Pyxis Oncology has a 12 month low of $0.99 and a 12 month high of $6.18. The company has a market cap of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The business had revenue of $16.15 million during the quarter.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently made changes to their positions in the company. Intech Investment Management LLC purchased a new stake in Pyxis Oncology in the 3rd quarter worth about $55,000. ProShare Advisors LLC bought a new position in shares of Pyxis Oncology during the fourth quarter valued at approximately $26,000. MetLife Investment Management LLC raised its holdings in shares of Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares during the period. Ameriprise Financial Inc. bought a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $35,000. Finally, Caption Management LLC purchased a new position in Pyxis Oncology during the 4th quarter valued at $35,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.